Atom Investors LP 89bio, Inc. Transaction History

Atom Investors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $73,060 - $175,849	10,970 New	10,970 $122,000
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $52,765 - $82,149	-3,729 Reduced 20.94%	14,081 $266,000
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $186,648 - $301,701	17,810 New	17,810 $271,000
Q3 2022 Nov 08, 2022	BUY	$3.02 - $7.0 $263,235 - $610,148	87,164 New	87,164 $505,000

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.